Biogen

YTD

ALL

Trade Biogen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.

CEO

Christopher A. Viehbacher

CEOChristopher A. Viehbacher

Employees

7,605

Employees7,605

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

1978

Founded1978

Employees

7,605

Employees7,605

BIIB Key Statistics

Market cap

17.36B

Market cap17.36B

Price-Earnings ratio

10.60

Price-Earnings ratio10.60

Dividend yield

—

Dividend yield—

Average volume

2.03M

Average volume2.03M

High today

$118.77

High today$118.77

Low today

$114.66

Low today$114.66

Open price

$115.02

Open price$115.02

Volume

1.21M

Volume1.21M

52 Week high

$238.00

52 Week high$238.00

52 Week low

$110.04

52 Week low$110.04

BIIB News

Benzinga 3d

Europe Approves Eisai-Biogen's Alzheimer's Drug 'Under Strict Conditions' After Initial Negative Opinion

The European Commission (EC) on Tuesday approved Eisai Co., Ltd. ESALY and Biogen Inc.’s BIIB amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab), The Co...

TipRanks 4d

Biogen reports EC grants marketing authorization for Leqembi

The European Commission has granted the amyloid-beta monoclonal antibody Leqembi Marketing Authorization in the European Union. Lecanemab is indicated for the t...

Analyst ratings

54%

of 37 ratings

Buy

45.9%

Hold

54.1%

Sell